AML-751: Clinical Efficacy and Safety of Enasidenib in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Department
Internal Medicine
Document Type
Conference Proceeding
Publication Title
Clinical Lymphoma Myeloma and Leukemia
Conference Name
Society of Hematologic Oncology (SOHO) Annual Meeting
Conference Date
2025-09-03 - 2025-09-06
First Page
S455
DOI
10.1016/S2152-2650(25)01721-5
Volume
25
Issue
Supplement 1
Publication Date
9-1-2025
Recommended Citation
Mylavarapu, M., Kodali, L. S., Ganatra, N., Medarametla, R., Pasnoor, D. S., Sanjeevi, A., & Jain, P. (2025). AML-751: Clinical Efficacy and Safety of Enasidenib in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Lymphoma Myeloma and Leukemia, 25 (Supplement 1), S455. https://doi.org/10.1016/S2152-2650(25)01721-5
COinS